Validation of a new fluorogenic real-time PCR assay for detection of CYP2C9 allelic variants and CYP2C9 allelic distribution in a German population

British Journal of Clinical Pharmacology

Volumn 54, Issue 5, 2002, Pages 518-521

  Burian, Maria ^a   Grösch, Sabine ^a   Tegeder, Irmgard ^a   Geisslinger, Gerd ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

CYP2C9; Ethnic differences; Genetic polymorphism; Light Cycler

Indexed keywords

CYTOCHROME P450 2C9;

ARTICLE; CAUCASIAN; CONFIDENCE INTERVAL; DEVICE; DNA EXTRACTION; GENE FREQUENCY; GENOTYPE; GERMANY; HUMAN; POLYMERASE CHAIN REACTION; POPULATION GENETICS; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; WILD TYPE;

ARYL HYDROCARBON HYDROXYLASES; BASE PAIR MISMATCH; FLUORESCENCE; GENOTYPE; GERMANY; HUMANS; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; VARIATION (GENETICS);

EID: 0036434235     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2002.01693.x     Document Type: Article

References (11)

1. Rettie AE, Wienkers LC, Gonzalez FJ, Trager WF, Korzekwa KR. Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics 1994; 4: 39-42.
2. Sullivan-Klose TH, Ghanayem BI, Bell DA, et al. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 1996; 6: 341-349.
3. Steward DJ, Haining RL, Henne KR, et al. Genetic association between sensitivity to warfarin and expression of CYP2C9*3. Pharmacogenetics 1997; 7: 361-367.
4. Ninomiya H, Mamiya K, Matsuo S, Ieiri I, Higuchi S, Tashiro N. Genetic polymorphism of the CYP2C subfamily and excessive serum phenytoin concentration with central nervous system intoxication. Ther Drug Monit 2000; 22: 230-232.
5. Stubbins MJ, Harries LW, Smith G, Tarbit MH, Wolf CR. Genetic analysis of the human cytochrome P450 CYP2C9 locus. Pharmacogenetics 1996; 6: 429-439.
6. van der Weide J, Steijns LS, van Weelden MJ, de Haan K. The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement. Pharmacogenetics 2001; 11: 287-291.
7. Aynacioglu AS, Brockmoller J, Bauer S et al. Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin. Br J Clin Pharmacol 1999; 48: 409-415.
8. Bhasker CR, Miners JO, Coulter S, Birkett DJ. Allelic and functional variability of cytochrome P4502C9. Pharmacogenetics 1997; 7: 51-58.
9. Scordo MG, Aklillu E, Yasar U, Dahl ML, Spina E, Ingelman-Sundberg M. Genetic polymorphism of cytochrome P460 2C9 in a Caucasian and a black African population. Br J Clin Pharmacol 2001; 52: 447-50.
10. Garcia-Martin E, Martinez C, Ladero JM, Gamito FJ, Agundez JA. High frequency of mutations related to impaired CYP2C9 metabolism in a Caucasian population. Eur J Clin Pharmacol 2001; 57: 47-9.
11. Yoon YR, Shon JH, Kim MK, Lim YC, Lee HR, Park JY, et al. Frequency of cytochrome P450 2C9 mutant alleles in a Korean population. Br J Clin Pharmacol 2001; 51: 277-80.